The global glioblastoma multiforme treatment market size is expected to hit around US$ 10.2 billion by 2030, according to a new report by Vision Research Reports.
The global glioblastoma multiforme treatment market size is expected to hit around US$ 10.2 billion by 2030, according to a new report by Vision Research Reports.
The global glioblastoma multiforme treatment market size was valued at US$ 5.14 billion in 2020 and is anticipated to grow at a CAGR of 12.8% during forecast period 2021 to 2030.
Report Highlights
- Radiation therapy dominated the market with a revenue share of 37.65% in 2020 owing to the improved survival rates.
- The hospitals segment held the largest share of 49.23% in 2020 and is anticipated to maintain its lead during the forecast period.
- North America accounted for the largest share of 43.65% in 2020.
- Asia Pacific is expected to register the fastest growth rate of 10.26% over the forecast period.
Immediate Delivery Available | Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/38479
Growth Factors
The market is driven by the rising prevalence of the disease and increasing approval for novel therapy and combination therapy. In recent years, the industry has been growing rapidly owing to the introduction of innovative products and rising interest of major pharmaceutical companies in the market due to favorable guidelines and rising incidence of the disease. For instance, companies such as Bristol Myers Squibb; CNS Pharmaceuticals, Inc.; and Bayer have novel products in the pipeline for glioblastoma multiforme. These products are likely to boost competitive rivalry in the market in the coming years. The growing prevalence of glioblastoma multiforme, increasing R&D, and favorable regulatory scenarios are among the factors anticipated to fuel the market growth. The presence of a strong pipeline is expected to act as a major driver for the glioblastoma multiforme (GBM) treatment market during the forecast period.
| Report Coverage | Details |
| Market Size | USD 10.2 Billion by 2030 |
| Growth Rate | CAGR of 12.8% From 2021 to 2030 |
| Base Year | 2020 |
| Historic Data | 2017 to 2020 |
| Forecast Period | 2021 to 2030 |
| Segments Covered | Treatment, Drug class, End-use |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Companies Mentioned | Merck & Co., Inc.; Amgen, Inc.; F. Hoffmann-La Roche Ltd.; Pfizer Inc.; Amgen, Inc.; Teva Pharmaceutical Industries Ltd.; Sun Pharmaceutical Industries Ltd.; Arbor Pharmaceuticals, LLC; Amneal Pharmaceuticals; Karyopharm Therapeutics, Inc.; Sumitomo Dainippon Pharma Oncology, Inc. (Boston Biomedical, Inc.) |
Report Highlights
Radiation therapy dominated the market with a revenue share of 47.6% in 2020 owing to the improved survival rates. Radiation therapy can be recommended as the first treatment or combined with chemotherapy and surgery. It is also effective and highly recommended for brain tumors in case of recurrence. The use of temozolomide along with radiotherapy makes the tumor more sensitive to radiation. This combination of therapy is more effective than radiation without temozolomide.
The others segment accounted for the largest revenue share of 76.4% in 2020. The other drugs segment includes drugs such as everolimus, corticosteroids, and 5-aminolevulinic acid (5-ALA). Corticosteroids are mainly prescribed to reduce the peritumoral vasogenic edema for symptomatic benefits. Dexamethasone is mainly prescribed due to its lack of mineralocorticoid activity.
North America accounted for the largest share of 53.6% in 2020. Government support for the development of the healthcare sector, high awareness about rare disorders, easy accessibility of quality medical facilities, and favorable reimbursement policies are among the key factors responsible for the regional market growth.
Market dynamics
Growing prevalence of glioblastoma multiforme
Approximately 80% of all central nervous system (CNS) primary malignant tumors are Glioblastoma multiforme (GBM). It is classified as a grade 4 astrocytic and oligodendroglial tumor by the World Health Organization. There is a demand for early detection and diagnosis. Advent of new technology has propelled the global glioblastoma multiforme treatment market.
Increasing research and development (R&D)
Various new biological drugs are introduced each year due to increasing R&D activities in molecular biotechnology and gene therapy for malignant diseases. These news drugs assist is reducing side effects of treatments and create more acceptance amongst patients. The approval of new treatment options will increase the life expectancy of patients living with glioblastoma multiforme. Furthermore, increasing collaborations between drug researchers and patients will bolster this market’s growth
Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/38479
Increasing drug approvals
Due to the high fatality rate of this disease, the glioblastoma multiforme treatment industry has witnessed numerous drug approvals in recent years. Moreover, the increase of activities by the regulatory authorities to approve new treatments has further bolstered this market growth.
Market challenges
High cost of glioblastoma multiforme treatment
The diagnostic tools and techniques used for the diagnosis of glioblastoma multiforme include:
- Radiation therapy
- Chemotherapy
Glioblastoma multiforme is usually diagnosed at advanced stages and this often results in a poor prognosis. Developing drugs for GBM is a highly complex and costly process that requires significant investments, clinical trial expertise, quality systems, scientific standards and technical capabilities. Drug manufacturers are required to invest in clinical trials and post-approval safety monitoring programs due to stringent regulations required by the regulators. Treating GBM using new and advanced drugs and the high cost associated with it will act as a major restraining factor for growth of this market
Key Market Trends
Chemotherapy Segment is Expected to Dominate the Market Over the Forecast Period
The chemotherapy segment is expected to dominate the market. The key factors contributing to the growth of the segment are the rising number of brain and other nervous system cancers and the growing preference and commercial availability of chemotherapeutic agents for treating glioblastoma.
As per the study titled “Glioblastoma Multiforme” published in the National Library of Medicine in November 2021, Glioblastoma multiforme (GBM) has a low overall survival rate and a high rate of recurrence, owing to its aggressive character. After surgical resection, radiation and chemotherapy are the mainstays of treatment. Furthermore, according to a study titled “Current Immunotherapies for Glioblastoma Multiforme” published in Frontiers of Immunology in March 2021, in clinical studies against GBM, combinatorial therapy of PD-1/PD-L1 antibodies with radiation therapy and/or chemotherapy appears to be more promising than monotherapy with PD-1/PD-L1 inhibitors, which has had limited effectiveness.
Likewise, many companies are focusing on developing and approving newer drugs for neurological diseases like brain stroke as well as glioblastoma to maintain their competitive edge and penetrate new regional markets across the developed and emerging regions. For instance, in July 2020, the United States Food and Drug Administration granted Denovo Biopharma’s DB102 (enzastaurin) fast-track designation for the treatment of patients newly diagnosed with glioblastoma. In addition, the pipeline of glioblastoma multiforme is strong with the number of drugs that are expected to receive FDA approval steadily over the coming years.
Additionally, a study titled “Glioblastoma: Pathogenesis and Current Status of Chemotherapy and Other Novel Treatments” published on PubMed.gov in April 2020 stated that for patients with glioblastoma, three chemotherapeutic drugs (temozolomide, bevacizumab, and carmustine) are currently available. The addition of temozolomide to radiation considerably increases overall survival, according to the findings of a randomized clinical trial including 573 patients (27.2% vs. 10.9% in the radiotherapy alone at 2 years). According to the same study, the methylation of the O6-methylguanine-DNA-methyltransferase (MGMT) gene was a strong predictive indicator for temozolomide chemotherapy in newly diagnosed patients.
Thus, all the aforementioned factors are anticipated to boost the segment over the forecast period.
Treatment Insights
Radiation therapy dominated the market with a revenue share of 37.65% in 2020 owing to the improved survival rates. Radiation therapy can be recommended as the first treatment or combined with chemotherapy and surgery. It is also effective and highly recommended for brain tumors in case of recurrence. The use of temozolomide along with radiotherapy makes the tumor more sensitive to radiation. This combination of therapy is more effective than radiation without temozolomide.
Surgery is the most common treatment for GBM, followed by radiation therapy and chemotherapy. This treatment plan is accepted as the standard of care. Moreover, the increasing use of targeted therapy to manage GBM is expected to fuel the segment growth during the forecast period. Rising research activities to develop novel targeted therapy for the disease are also anticipated to boost the segment growth.
Drug Class Insights
The others segment accounted for the largest revenue share of 66.51% in 2020. The other drugs segment includes drugs such as everolimus, corticosteroids, and 5-aminolevulinic acid (5-ALA). Corticosteroids are mainly prescribed to reduce the peritumoral vasogenic edema for symptomatic benefits. Dexamethasone is mainly prescribed due to its lack of mineralocorticoid activity. Furthermore, the use of corticosteroids may have immunosuppressive effects that emphasize the opportunities to target immune response for targeted therapy.
Bevacizumab is a targeted therapy approved for the treatment of recurrent and newly diagnosed GBM. Furthermore, in December 2017, the company received full approval from the U.S. FDA for bevacizumab for the treatment of adults with GBM. The medication is administered intravenously to stop the formation of new blood vessels that cut the blood supply and help reduce the tumor. Continuation in clinical studies to use bevacizumab with other therapies is expected to increase the usage of the drug for the management of GBM.
End-use Insights
The hospitals segment held the largest share of 49.23% in 2020 and is anticipated to maintain its lead during the forecast period. Hospitals are preferred by patients in terms of treatment accessibility and convenience. Moreover, a high number of surgeries performed to manage GBM and the complexity associated with the treatment are anticipated to drive the market.
The clinics segment is expected to grow at the fastest rate over the forecast period. Increasing adoption of noninvasive therapies, such as radiation therapy and tumor-treating fields therapy, is anticipated to drive the segment. Increasing adoption of noninvasive and patient-oriented treatment, such as external beam radiation therapy and tumor-treating fields therapy, is anticipated to boost segment growth. For instance, Johns Hopkins Medicine offers radiation therapy, tumor-treating fields therapy, and others for the treatment of brain cancer.
The ambulatory surgical centers segment is expected to witness lucrative growth over the forecast period. An increasing number of complex surgeries performed in an outpatient setting may increase the brain tumor resections at ambulatory surgical centers.
Regional Insights
North America accounted for the largest share of 43.65% in 2020. Government support for the development of the healthcare sector, high awareness about rare disorders, easy accessibility of quality medical facilities, and favorable reimbursement policies are among the key factors responsible for the regional market growth.
Asia Pacific is expected to register the fastest growth rate of 10.26% over the forecast period owing to various factors such as entry of generics of temozolomide in the market, improving economy, rising geriatric population, and growing investments in the healthcare sector. The presence of large unmet needs in the market, growing awareness about GBM, and the presence of a robust pipeline (molecules with the ability to bypass the blood-brain barrier) are among the key factors contributing to the regional market growth.
Key Players
- Merck & Co., Inc.
- Amgen, Inc.
- F. Hoffmann-La Roche Ltd.
- Pfizer Inc.
- Amgen, Inc.
- Teva Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Ltd.
- Arbor Pharmaceuticals, LLC
- Amneal Pharmaceuticals
- Karyopharm Therapeutics, Inc.
- Sumitomo Dainippon Pharma Oncology, Inc. (Boston Biomedical, Inc.)
Market Segmentation
- Treatment
- Surgery
- Radiation Therapy
- Chemotherapy
- Targeted Therapy
- Tumor Treating Field (TTF) Therapy
- Immunotherapy
- Drug Class
- Temozolomide
- Bevacizumab
- Lomustine
- Carmustine Wafers
- Others
- End-use
- Hospitals
- Clinics
- Ambulatory Surgical Centers
- Regional
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Click Here to View Full Report Table of Contents
Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/38479
You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333
Blog: https://www.novaoneadvisor.com/
Blog: https://qyresearchmedical.com/